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Abstract
Purpose A tele-patient-reported outcome (telePRO)
model includes outpatients’ reports of symptoms and
health status from home before or instead of visiting the
outpatient clinic. In the generic PRO system, AmbuFlex,
telePRO is used to decide whether a patient needs an
outpatient visit and is thus a tool for better symptom
assessment, more patient-centred care, and more efficient
use of resources. Specific PROs are developed for each
patient group. In this paper we describe our experiences
with large-scale implementations of telePRO as the basis
for follow-up in chronic and malignant diseases using the
generic PRO system AmbuFlex.
Methods The AmbuFlex concept consists of three generic
elements: PRO data collection, PRO-based automated
decision algorithm, and PRO-based graphical overview for
clinical decision support. Experiences were described with
respect to these elements.
Results By December 2015, AmbuFlex was implemented
in nine diagnostic groups in Denmark. A total of 13,135
outpatients from 15 clinics have been individually referred.
From epilepsy clinics, about 70 % of all their outpatients
were referred. The response rates for the initial question-
naire were 81–98 %. Of 8256 telePRO-based contacts from
epilepsy outpatients, up to 48 % were handled without
other contact than the PRO assessment. Clinicians as well
as patients reported high satisfaction with the system.
Conclusion The results indicate that telePRO is feasible
and may be recommended as the platform for follow-up in
several patient groups with chronic and malignant diseases
and with many consecutive outpatient contacts.
Keywords Patient-reported outcomes  telePRO  ePRO 
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Background
The use of patient-reported outcomes (PRO) in clinical
practice is becoming increasingly common, and several
studies have reported improved patient–clinician commu-
nication, early recognition of important symptoms, more
effective self-management, and better use of resources [1–
7]. A PRO measure is the patient’s own report of health
status, e.g. symptoms, health-related quality of life, and
functional status. The American Food and Drug Agency
defines PRO as ‘‘A measurement based on a report that
comes directly from the patient about the status of a
patient’s health condition without interpretation of the
patient’s response by a clinician or anyone else’’ [8]. This
definition focuses on the source of information and
emphasises the importance of the patient perspective.
Experiences of use of electronic PRO (ePRO) systems
have been extensively reported [1–7, 9–12]. The primary
goal is to improve quality of care by better support of
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clinical activities, e.g. prospectively symptom monitoring
used as consultation support. Haverman et al. [13] describe
an ePRO system in daily paediatric clinical practice
developed to systematically monitor health-related quality
of life (HRQOL) in children with a chronic arthritic dis-
ease, and Snyder et al. [14] describe the development of the
website PatientViewpoint, designed to collect PRO in
outpatient clinical oncology. Both systems use PRO before
a scheduled consultation, but Snyder et al. [14] emphasise
the potential of using PRO between visits.
Integrating PRO into clinical practice has great potential
when PRO becomes a central part of the patient pathway
and is fully incorporated into daily clinical practice [15].
Follow-up for patients with chronic diseases is traditionally
lifelong and managed by regular pre-scheduled visits.
These visits may occur when the patient is well, and neither
the patient nor the clinician finds the visit necessary [16].
Unnecessary outpatient visits place an increasing burden
on already overstretched healthcare services, making it
difficult to respond rapidly to a patient’s acute requests for
attention [16, 17]. A PRO assessment can be used to
evaluate the need for a clinical visit, thereby managing
resources better [18]. Outpatient clinics could potentially
minimise large numbers of routine visits if a PRO assess-
ment is obtained when the patient is still at home. The
benefit comes from making PRO the basis for outpatient
follow-up instead of now—the patient visit [15]. However,
few attempts, if any, have been made to make PRO the
basis for outpatient follow-up [15].
In ePRO systems, PRO data may be collected at home or
in the waiting room using computers, tablets or a patient
kiosk. If PRO is used as the basis for outpatient follow-
up—and even a replacement of unnecessary visits, PRO
data must obviously be collected at a distance (e.g. from
home), and we will refer to the latter as telePRO [18].
AmbuFlex is a generic clinical telePRO system for
mixed-mode (web and paper) PRO data collection for use
in clinical practice. The overall goal is to use PRO for
clinical decision support to improve quality of care, pro-
mote patient-centred care, optimise the use of resources in
the healthcare system, and use data for research purpose
(Table 1).
The aim of this paper was to describe experiences with
implementing telePRO as the basis for follow-up in chronic
and malignant diseases using the generic PRO system
AmbuFlex, where the patients define the need of an out-
patient consultation by delivering PRO.
Methods
AmbuFlex is the frontend of the WestChronic system, used
for research purposes in clinical epidemiological studies
since 2004 [18]. AmbuFlex consists of three generic,
configurable elements (Table 2) [18]: PRO data collection,
PRO-based automated decision algorithm, and PRO-based
graphical overview for clinical decision support. We
describe our experiences with respect to these three
elements.
PRO data collection
The development of the disease-specific PRO questionnaire
is fundamental for the validity, reliability, and acceptability
to patients and clinicians [19]. It is vital that the ques-
tionnaire reflects clinically relevant aspects of the actual
clinical situation. Clinicians as well as patients must find
all items in the questionnaire relevant. Face validity was
ensured during the development process for each new
patient group. If clinically relevant validated instruments
were not available, we developed ad hoc items if necessary.
This process included inputs from specialists in the disease
area, a review of literature, and an interview with patients
[20]. We only developed ad hoc items, not scales. Pilot
tests of questionnaires were conducted to identity potential
problems such as low relevance of items, ambiguity of
items, and lack of important issues [21, 22]. The AmbuFlex
system automatically prompts patients by letter or e-mail to
answer the questionnaire either online or in paper form at a
scheduled time, and therefore referral is a prerequisite.
TelePRO referral is managed as part of daily clinical
practice and decided by the individual clinician based on
patient characteristics and his or her experiences and
preferences. Information on the mixed-mode data collec-
tion (web-based, paper-based, or mixed-mode) and other
logistics considerations related to administration, such as
reminders and data import and export are reported else-
where [18].
Table 1 General aims in telePRO projects
Improve quality of care by flagging important symptoms and produce better documentation of patient information
Promote patient-centred care with focus on patients’ needs and knowledge about own disease
Optimise the use of resources in the healthcare system
Use PRO data in research and hospital quality assurance
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PRO-based automated decision algorithm
AmbuFlex is designed to make automated decisions, in which a
PRO assessment is used to divide patients into two categories:
those who need clinical attention and those who do not based on
defined algorithms and thresholds. Two different approaches
were used: external cut-off values based on validated PRO
instruments or thresholds defined by clinicians where each
response category was assigned a colour code. When a
threshold was defined by clinicians, the goal was to have a false-
negative rate close to zero, whereas the rate of false positive was
of less concern [18]. A clinical expert group divided each
response categories into three levels: green, yellow, or red.
These assignments were entered into the server software’s
configuration utility for each specific questionnaire. Based on
the incoming PRO data, the server algorithms would consec-
utively categorise the patients’ present state. If all responses had
a green code, it would signal that no contact was needed; if one
or more responses had a red code, the patient must be seen or
contacted; while a yellow code indicated that the patient may
need to be contacted and a clinician should make the decision
based on the PRO overview (cf. below). The AmbuFlex system
keeps track of patients with red and yellow status and non-
responders, who are presented to the clinicians on an alert list.
PRO-based graphical overview for clinical decision
support
A clinical PRO system should enable the clinician to access
systematically collected PRO data to support monitoring and
clinicaldecision-making [1, 19]. AmbuFlex uses the PRO data to
display the course of symptoms and prioritises issues by flagging
symptoms that need further attention. A graphical overview
presented to the clinician can guide clinical decisions. A
graphical PRO overview interface was developed, and a con-
figuration utility enables adaption to the specific patient group.
Results
As of December 2015, AmbuFlex has been implemented in
nine diagnostic groups in Denmark. This paper included seven
clinical projects with internal project management by
AmbuFlex funded by Central Denmark Region, one ran-
domised controlled trial with external project management
funded by Aarhus University Hospital, and one clinical pro-
ject with external project management funded by the Danish
Cancer Society. The characteristics of all projects are pre-
sented in Table 3. In addition to the general aims in Table 1,
each implementation had additional aims according to the
specific diagnostic group. In epilepsy (b), narcolepsy (c), sleep
apnoea (e), prostate cancer (f), asthma (h), and renal failure (i),
the aim was to facilitate greater flexibility in the provision of
care and thereby increase patient self-management, improve
the quality of care, and achieve a better utilisation of resour-
ces. In rheumatoid arthritis (d), the primary aim was to
examine the effect of a PRO-based telemedicine intervention
to assess flare-ups in disease activity using a validated PRO
instrument [23, 24] combined with a blood test. In colorectal
cancer (g), one of the aims was to use PRO data to assess a
patient’s health status before chemotherapy treatment in order
to prescribe the chemotherapy in advance. In coronary heart
disease (a), the primary aim was to screen patients for
depression and anxiety.
PRO data collection
Questionnaire and pilot tests
The questionnaires were, whenever possible, based on
validated PRO instruments, e.g. WHO-5 [26], SF-36 [27],
HADS [25], EORTC QLQ-C30 [32]. Ad hoc items were
developed in five projects (Table 3). All questionnaires
were pilot-tested by the patients. For example, a total of 20
outpatients with epilepsy were included to pretest the epi-
lepsy questionnaire. The majority of patients found the
questionnaire easy to use apart from some problems due to
recall and linguistic skills. They perceived the items as
relevant and did not report any lack of important issues.
The questionnaire provided important information specific
to aspects of daily life with epilepsy. After a pilot test, the
PRO application was implemented, and experiences with
the questionnaire were continuously evaluated. Items were
revised in an iterative process until saturation was reached
after 2–4 months. After this period only few minor changes
were usually needed [18].
Table 2 Elements of clinical application of tele-patient-reported outcomes (telePRO) [18]
A. PRO data collection Questionnaire and pilot tests
Referral
Data collection modes
B. PRO-based automated decision algorithm Thresholds defined by published cut-off values
Thresholds defined by clinicians
C. PRO-based graphical overview for clinical decision support Course-oriented graphic overview
Configuration of PRO for clinical decision support
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Referral
All patients were individually referred, and a total of 13,135
outpatients from 15 clinics have been referred to telePRO
follow-up. In epilepsy, it was estimated that 70 % of all
outpatients were referred. Numbers of referred patients in
each specific project by December 2015 are listed in Table 3.
Criteria for referral differed between the diagnostic groups
due to the use of different guidelines for monitoring the
disease course. In epilepsy (b), narcolepsy (c), sleep apnoea
(e), and prostate cancer (f), the patients were referred to
AmbuFlex by the clinician, hence received questionnaires at
pre-specified intervals (3, 6, or 12 months). Patients with
rheumatoid arthritis (d) and asthma (h) were referred with a
3-month interval between questionnaires.
Data collection modes
PRO data were collected with mixed-mode (paper or web-
based) in all projects except two, where only the web-based
method was applied due to a tight time schedule [colorectal
cancer (g) and asthma (h)]. Up to three reminders were
applied (Table 3). A total of 18,912 questionnaires have been
collected. The response rates for the initial questionnaire
ranged from 81 to 98 % (Table 3). The highest rates were
found among patient with prostate cancer (f) (98 %), nar-
colepsy (c) (98 %), and sleep apnoea (e) (95 %). The lowest
rate was found among patients with heart disease (a) (81 %),
and renal failure (i) (84 %), where only one reminder was
used. During follow-up, the rates were between 90 and 98 %.
The average proportion of web-based answers was 56.7 %.
PRO-based automated decision algorithm
Thresholds defined by published cut-off values
This method was used in patients with heart disease (a),
rheumatoid arthritis (d), and asthma (h). In rheumatoid
arthritis (d), published cut-off values [23, 24] were used
combined with objective data (blood test indicating
inflammation) to indicate when the patient should be seen
in the clinic. In patients with coronary heart disease (a), an
automated algorithm based on published cut-off values
divided patients into nine groups according to no, moder-
ate, or severe symptoms on the two scales of anxiety and
depression [25]. Based on these values, the AmbuFlex
system automatically generated a personalised letter with
screening results. If moderate or severe symptoms were
present, the patient was advised to consult his general
practitioner and bring along the letter [18].
Thresholds defined by clinicians
This method was used in patients with epilepsy (b), narcolepsy
(c), sleep apnoea (e), prostate cancer (f), and colorectal cancer
(g). In epilepsy (b), examples of red responses were self-re-
ported aggravation of seizures or planning of pregnancy.
Examples of yellow responses were self-reported presence of
one or more symptoms (e.g. headache, dizziness and tremor) or
social difficulties. Patients could in all cases request a contact
and overrule any automated decision of ‘‘no contact’’ when
answering the question ‘‘Which form of consultation do you
feel would be most appropriate for you at this point in time?’’. If
their answer was ‘‘I would like the clinic to contact me’’ or ‘‘I
would like to book an appointment’’, the response was always
determined to be red. Distribution of green, yellow, and red
responses in epilepsy, sleep apnoea, prostate cancer, and heart
disease is presented in Table 4. In epilepsy and sleep apnoea, 48
and 57 %, respectively, of the incoming PRO questionnaires
could be handled with no other contact than the PRO. In epi-
lepsy, the distribution is illustrated in Fig. 2.
PRO-based graphical overview for clinical decision
support
Course-oriented graphic overview
A graphical overview of the PRO results over time was
designed in each AmbuFlex implementation, and presented
graphically to the clinician (Fig. 1). The overview was
Table 4 Distribution of PRO-based automated decisions and patient contact to the clinic in four telePRO projects, December 2015









to the clinic %
Contact to
the clinica %
Epilepsy 8256 1035 (12) 5110 (62) 2111 (26) 48 52
Sleep apnoea 1424 202 (14) 673 (47) 549 (39) 57 43
Prostate cancer 347 38 (11) 128 (37) 181 (52) 26 74
Heart diseaseb 1335 932 (69.8) 0 403 (30.2) n/a n/a
a Contact to the clinic: a telephone consultation or a visit at the outpatient clinic
b Hospital Anxiety and Depression Scale (HADS) [25] in patients with cardiovascular disease 2011–2013. All patients received a letter with
screening results. Patient with red status (moderate or severe symptoms) were advised to consult his general practitioner (GP) and bring along the
letter. n/a: Data of contact to the GP is not available
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integrated via a link to the electronic health record system in 13
out of 15 outpatient clinics in one Danish region, whereas the
other clinics accessed the database via an external secure
webpage. Each vertical column in Fig. 1 represents a PRO
questionnaire. The items and responses were displayed as a
‘‘pop-up tip’’ when the user puts the mouse icon over the dis-
played bar. Vertically, the overview presented the actual situ-
ation and horizontally the change in response over time [18].
Configuration of PRO for clinical decision support
The process of selecting items and grading severity was
based on inputs from the clinicians. Colour codes were
used to graduate the severity of symptoms or mark atten-
tion to a worsening problem. Some items did not fit into the
overview, e.g. items with a yes/no response scale. All items
however, were available when clicking at ‘Show PRO’,
enabling the clinicians to see specific questionnaire
responses. In that way, clinicians got a complete list of all
questions and answers in the specific questionnaire with
detailed information about the items and colour codes.
Example: patient flow in outpatients with epilepsy
An overview of the patient flow for outpatients with epi-
lepsy is shown in Fig. 2. In December 2015, about 70 % of
Fig. 1 Screen capture of the clinicians’ overview in epilepsy clinics
accessed from the Electronic Health Record of Central Denmark
Region (MidtEPJ). The colour codes in the upper row indicate the
result of the automated PRO algorithm (red: definite need of contact,
yellow: possible need of contact, green: no need of contact). The bars
indicate the severity of the symptom, e.g. a red colour indicates a self-
reported problem. Note: Labels were translated from the Danish.
(Color figure online)
Fig. 2 Flow chart for outpatients with epilepsy, December 2015.
Green response: No need of contact. Yellow response: May need
contact. A clinician has to decide whether further contact is needed.
Red response: Definite need of contact or the patient asks for a
consultation. *Estimated response rate with first questionnaire was
92 %. (Color figure online)
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the population of outpatients with epilepsy (b) in Central
Denmark Region was referred to AmbuFlex (N = 4214). A
total of 9130 questionnaires were posted and 8256
responses have returned. The response rate was estimated
to be 92 % for the initial questionnaire and 95 % for the
subsequent ones. Among the 8256 responses, the distribu-
tion was as follows: green (12 %), yellow (62 %), and red
(26 %). In 38 % (green and red responses), the PRO-based
automated algorithm decided automatically whether the
patient should be seen or not. In the remaining 62 %, the
clinician most often (36 %) decided that no further contact
was needed. Overall, 48 % had no further contact than the
PRO, while 52 % had a subsequent follow-up visit in the
outpatient clinic or a telephone consultation.
Feedback from clinicians and patients
The AmbuFlex implementation process for each patient
group took place in one selected outpatient clinic (the
index department). Experiences showed that the system
was easily transferred to other outpatient clinics for the
same patient group without modification or with only a few
changes. Hence, an implementation seems to be specific for
a patient group, not for the organisation [18]. The imple-
mentation process in epilepsy has been positively evaluated
from a clinical as well as a patient perspective [39]. Both
system and questionnaire have been developed in close
cooperation with clinicians. Patients’ experiences of using
PRO in clinical practice have been positive. Patients did
not feel insecure with communication solely being written.
Overall, the patients reported several advantages including
greater flexibility in care, saving of time, improved infor-
mation to the clinicians, increased knowledge about their
own disease, and a good societal perspective in relation to
sympathising with other patients’ needs [39].
Discussion
So far, the generic PRO system AmbuFlex has been
implemented in nine diagnostic groups at 15 outpatient
clinics in Denmark. In these cases, telePRO was used as the
basis for the contact between the patient and the clinic. In
epilepsy clinics, up to 70 % of outpatients were referred to
telePRO-based follow-up, and up to 48 % of the incoming
PRO questionnaires could be handled with no other contact
than the PRO.
Although results from other large-scale PRO imple-
mentations have been reported [40–42], we have not been
able to identify other examples in which PRO was used
instead of scheduled visits and as the basis for the contact.
In nearly half of the cases, telePRO was the only contact
between the patient and the clinic. This is important for two
reasons. First, when telePRO is the basis for the contact, it
is no longer an optional or added task for patients and
clinicians, but fully integrated into the patient care. This
being achieved, the other potential benefits of PRO mea-
sures in clinical practice may be obtained such as improved
quality of care, better symptom assessment, more patient-
centred care, and more efficient use of resources [7, 42,
43]. Second, when potentially up to half of the visits may
be replaced by a less resource demanding activity, there
may be an economic argument for the shift to telePRO,
because the savings made could cover the expenses asso-
ciated with implementation of telePRO. A recent national
analysis of the clinical use of telePRO initiated by the
Danish government and Danish regions based solely on
experiences with AmbuFlex concluded that there was an
overall economical potential related to (1) cancelled con-
sultations, (2) reduced reimbursement of patient trans-
portation costs, and (3) reduced need of destruction of
medicine in cancer treatment. A national strategy for dis-
semination of clinical telePRO was therefore recom-
mended [44].
Implementation of telePRO in clinical practice involves
several issues related to the specific patient group, ques-
tionnaire, technology, and organisation [19, 41]. Unfortu-
nately, a PRO instrument with documented psychometric
properties relevant for the actual clinical decision is often
not available, especially in non-malignant diseases. In
other cases, a relevant PRO was available, but no relevant
cut-off values were documented. In these cases, the content
and cut-off values were negotiated based on iterative inputs
from clinicians, review of the literature, and interviews
with patients [18]. Reliability and other validity tests are of
great value in improving data quality. Reliability studies of
AmbuFlex questionnaire including developed ad hoc items
will be conducted in the future. The key issues in all
AmbuFlex implementations are involvement of patients as
well as support from frontline clinicians and administrative
leaders [18]. Since telePRO is used for clinical decisions,
even automatic decisions, strict attention to the sensitivity
should be given, and the algorithm should also reflect this.
To ensure high sensitivity, clinicians assigned a green,
yellow, or red colour to each item response in the ques-
tionnaires. More than about 15 % automatic green
responses can rarely be reached without compromising the
security in relation to detect patients in need of attention.
All outpatients are instructed to contact the clinic in case of
sudden worsening.
High response rates are needed to achieve satisfactory
rates of completion [41]. In the Dutch ePRO system KLIK,
an average of 70 % of patients have completed question-
naires prior to the consultation [45, 46], but in other sys-
tems only half of the patients completed the assessment
before a visit [42]. Patients’ health literacy can be a barrier
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when completing PROs [41] and should be taken into
account by the clinician before referring a patient to tele-
PRO follow-up. If high response rates are crucial, a mixed-
mode survey must be considered. Findings from ran-
domised studies in other patient populations support this
[47, 48]. We use a dual-mode system in which patients can
choose between web and paper questionnaires that results
in response rates beyond 90 %. This is discussed in more
detail elsewhere [18].
Health professionals value PRO data when they are
useful for the clinical decision-making process, whereas
potential barriers may arise when the use of PRO appears
to be disruptive to normal work flow [5, 49]. From the
clinicians’ perspective, telePRO information should be of
major importance in the clinical assessment of the dis-
ease, and a physical examination should not be central for
evaluation of the patients’ clinical status [18]. The clini-
cians have to reallocate resources to handle the incoming
questionnaires and have available time slots for consul-
tations when an appointment is needed. A potential barrier
in telePRO could be clinicians’ reluctance to an open-
access strategy, as clinicians may believe that most
patients would want to be seen in the outpatient clinic.
This is, however, not the case in outpatients with epilepsy,
as only 23 % ask for a consultation. Another barrier
related to successful implementation is clinicians’ lack of
knowledge on how to effectively utilise PRO data in their
clinical practice [45, 49]. Santana et al. [45] recommend
learning programmes teaching clinicians how to use and
react to PRO in clinical practice. We work closely with
frontline clinicians who are motivated; however, it can be
a challenging process to convince a medical staff who is
not enthusiastic about the use of PRO in clinical practice.
Training programmes could be useful in telePRO imple-
mentations increasing involvement and motivation in the
entire healthcare team.
Based on our experiences so far, we can suggest some
characteristics that should be fulfilled when considering a
patient group for telePRO. First, patients should need
regular and systematic disease monitoring with several
outpatient follow-up. Second, the disease activity and thus
the need of medical attention should vary over time. Third,
PRO should be essential for the clinical evaluation, if
necessary, together with laboratory data in the health
record, and finally, the evaluation of the health status
should obviously not depend on a physical examination,
e.g. auscultation (Table 5). We believe that a substantial
proportion of diagnostic groups in outpatient follow-up
fulfil these criteria.
There is a great potential in engaging patients more
extensively in PRO data collection and implementation.
For outpatients with epilepsy, we have now designed a
website, ‘‘My Epilepsy’’, where patients have access to
their own questionnaire responses, and contacts to the
outpatient clinic can be initiated by the patient based on a
PRO assessment. The website is linked with the Danish
National Health Website (‘Sundhed.dk’). A randomised
controlled study comparing the actual AmbuFlex with this
new open-access version is in progress. Based on the
results, this patient-centred follow-up approach will prob-
ably be used extensively in future telePRO implemen-
tations.
Conclusion
To our knowledge, AmbuFlex is the first generic PRO
system that has transferred follow-up of entire diagnostic
groups to a PRO platform for outpatient care. The
AmbuFlex system is generic and not limited to specific
diagnostic groups, organisations, or electronic medical
records. The system has been standard practice since
2012 in epilepsy outpatient clinics and subsequently in
eight other diagnostic groups. Experiences from the nine
telePRO implementations have shown an impact on the
organisation of patient care, since 48 % of the epilepsy
respondents did not need further contact with the clinic
other than the PRO itself. This could indicate the need
for a reorganisation of conventional care in the health-
care system. Finally, based on our experiences, we rec-
ommend use of telePRO for patients with chronic
diseases with many consecutive contacts, where PRO is
essential for clinical evaluation. In the implementation
process for new patient groups, involvement of patients
as well as frontline clinicians and administrative leaders
is essential.
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